EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Developing New Immunotherapy Approaches for Colorectal Cancer

Gregory Kelly iD, Bianca Nowlan iD, Simon Manuel Tria iD, Afshin Nikkhoo iD, Catherine Bond, Vicki Whitehall

Cancers · 09.12.2025 · 17 (24) · 3929

DOI: 10.3390/cancers17243929 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 09.12.2025. Verfasst von Gregory Kelly und 5 weiteren Autor:innen. Beteiligte Einrichtung: Conjoint Gastroenterology Laboratory, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, QLD 4006, Australia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy represents a groundbreaking approach for treating colorectal cancer (CRC), harnessing the body’s own immune system to target tumour cells more precisely than conventional chemotherapy. Immune checkpoint inhibitors, such as antibodies against PD-1, PD-L1, or CTLA-4, have shown remarkable efficacy in certain patients, leading to durable responses and improved survival. However, the majority of CRC cases have limited benefit from a single agent checkpoint blockade. There is a growing need to identify biomarkers that will improve the selection of patients who will best respond to therapy, as well as new targets to sensitise cancers to an immune checkpoint blockade. Unfortunately, the search for reliable biomarkers has been limited by our incomplete understanding of how immunotherapies modify the already complex immune response to cancer. Revolutionary techniques, such as genome-wide CRISPR/Cas9 screening combined with the appropriate validation systems such as in vivo mouse models and/or 3D organoid co-culture systems, are being used to address this knowledge gap. This review will focus on the use of immunotherapies in CRC, discuss why most CRC patients do not respond, and highlight in vitro, in vivo, and novel techniques for discovery of new targets for combination treatment.

Schlagwörter

Stichwörter der Autor:innen

CRISPR/Cas9 screensco-culture modelscolorectal cancerimmunotherapyin vivo modelsorganoids

Autor:innen und Institutionen

  • Conjoint Gastroenterology Laboratory, QIMR Berghofer Medical Research Institute, Herston Rd, Herston, QLD 4006, Australia.
  • Faculty of Medicine, The University of Queensland, Brisbane, QLD 4102, Australia.
  • Conjoint Internal Medicine Laboratory, Queensland Health, Brisbane, QLD 4006, Australia.

ORCID-Profile: Gregory Kelly, Bianca Nowlan, Simon Manuel Tria, Afshin Nikkhoo

Zitieren

APA

Kelly, G., Nowlan, B., Tria, S. M., Nikkhoo, A., Bond, C., & Whitehall, V. (2025). Developing New Immunotherapy Approaches for Colorectal Cancer. Cancers, 17(24), 3929. https://doi.org/10.3390/cancers17243929

Vancouver

Kelly G, Nowlan B, Tria SM, Nikkhoo A, Bond C, Whitehall V. Developing New Immunotherapy Approaches for Colorectal Cancer. Cancers. 2025;17(24):3929. doi:10.3390/cancers17243929

BibTeX
@article{Kelly2025,
  author = {Kelly, Gregory and Nowlan, Bianca and Tria, Simon Manuel and Nikkhoo, Afshin and Bond, Catherine and Whitehall, Vicki},
  title = {Developing New Immunotherapy Approaches for Colorectal Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {24},
  pages = {3929},
  doi = {10.3390/cancers17243929}
}
Kostenlos starten →